Balyasny Asset Management LLC Catalyst Pharmaceuticals, Inc. Transaction History

Balyasny Asset Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$14.68 - $16.92 $760,644 - $876,709	51,815 New	51,815 $802,000
Q4 2023 Feb 14, 2024	BUY	$11.78 - $17.29 $676,961 - $993,604	57,467 New	57,467 $966,000
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $243,682 - $535,688	34,516 New	34,516 $443,000
Q2 2018 Aug 14, 2018	SELL	$2.26 - $3.84 $92,004 - $156,326	-40,710 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$2.39 - $4.01 $97,296 - $163,247	40,710 New	40,710 $97,000
Q4 2017 Feb 14, 2018	SELL	$2.51 - $4.4 $37,148 - $65,120	-14,800 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$2.4 - $2.94 $35,520 - $43,512	14,800	14,800 $37,000

327

94.6M

19.1K

51.1K

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.14B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.